EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06071013` - Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT05598528` - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Not yet recruiting	`NCT06018688` - Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.	Phase 2
Active, not recruiting	`NCT04013542` - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	Phase 1
Recruiting	`NCT05517083` - Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer	N/A
Not yet recruiting	`NCT04592666` - Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer	Phase 2
Active, not recruiting	`NCT03065387` - Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	Phase 1
Completed	`NCT03653546` - First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases	Phase 2/Phase 3
Active, not recruiting	`NCT02954523` - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations	Phase 1/Phase 2
Active, not recruiting	`NCT03732352` - 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma	Phase 2
Completed	`NCT04552613` - Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients	N/A
Completed	`NCT03755102` - A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	Early Phase 1
Recruiting	`NCT02338011` - Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)	Phase 2/Phase 3
Active, not recruiting	`NCT04085315` - Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	Phase 1
Not yet recruiting	`NCT06117644` - The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Recruiting	`NCT03396185` - Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer	Phase 2
Recruiting	`NCT03042221` - Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Not yet recruiting	`NCT06222489` - Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT	Phase 2

NCT number	NCT03720873
Study type	Interventional
Source	Fujian Cancer Hospital
Contact	Zhiyong He, master
Phone	13805086391
Email	heyong1015@163.com
Status	Recruiting
Phase	Phase 2
Start date	October 2018
Completion date	September 2022

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms